title: Soluble vascular endothelial (VE) cadherin and autoantibodies to VE-cadherin in rheumatoid arthritis patients treated with etanercept or adalimumab.
abstract: OBJECTIVE
  The aim of this study was to investigate the clinical value of sVE and anti-vascular endothelial-cadherin antibodies (AAVE) in RA treated with etanercept or adalimumab combined with methotrexate.
  
  
  METHODS
  This was an 18-month prospective multicenter study in which patients had active RA, requiring TNF antagonist. sVE rates and AAVE titers were measured respectively by dot blot and ELISA. The relationship of these biomarkers with parameters reflecting articular or systemic disease activity, progression of structural damage, and response or remission to treatment was analyzed.
  
  
  RESULTS
  Forty-eight patients received TNF blocking agents. Variation of sVE rates were significantly correlated with that of C-reactive protein (CRP) levels at weeks 6, 12, 26 and 52. A significant decrease in sVE levels was observed in the group of patients exhibiting a decrease in CRP levels as compared to the patient group with unmodified CRP. AAVE at baseline were correlated with rheumatoid factor. Kinetics analysis of sVE levels and AAVE titers showed that their level were not associated with disease activity score and to methotrexate/adalimumab or etanercept response.
  
  
  CONCLUSIONS
  sVE is a biomarker associated with systemic RA activity under anti-TNF. AAVE are related to autoantibodies usually associated to RA.
authors.affiliation: Rheumatology Department, Rouen University Hospital, Inserm U905, CIC/CRB 1404, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, 76000 Rouen, France. Electronic address: Christopher.Banse@chu-rouen.fr.
authors.forename: Christopher
authors.initials: C
authors.lastname: Banse
authors.affiliation: Inserm, Unit 1036, Biology of Cancer and Infection, 38054 Grenoble, France; UJF-Grenoble 1, Biology of Cancer and Infection, 38054 Grenoble, France; CEA Comission at Atomic Energy and Alternative Energies, DRF/B(2)IG direction de la recherche fondamentale/BioScience and Biotechnology Institute of Grenoble, 38054 Grenoble, France.
authors.forename: Helena
authors.initials: H
authors.lastname: Polena
authors.affiliation: Inserm, Unit 1036, Biology of Cancer and Infection, 38054 Grenoble, France; UJF-Grenoble 1, Biology of Cancer and Infection, 38054 Grenoble, France; CEA Comission at Atomic Energy and Alternative Energies, DRF/B(2)IG direction de la recherche fondamentale/BioScience and Biotechnology Institute of Grenoble, 38054 Grenoble, France.
authors.forename: Barry
authors.initials: B
authors.lastname: Stidder
authors.affiliation: Inserm, Unit 1036, Biology of Cancer and Infection, 38054 Grenoble, France; UJF-Grenoble 1, Biology of Cancer and Infection, 38054 Grenoble, France; CEA Comission at Atomic Energy and Alternative Energies, DRF/B(2)IG direction de la recherche fondamentale/BioScience and Biotechnology Institute of Grenoble, 38054 Grenoble, France.
authors.forename: Abir
authors.initials: A
authors.lastname: Khalil-Mgharbel
authors.affiliation: Department of Biostatistics, Rouen University Hospital, IRIB, University of Rouen, 76031 Rouen, France.
authors.forename: Estelle
authors.initials: E
authors.lastname: Houivet
authors.affiliation: Rheumatology Department, Rouen University Hospital, Inserm U905, CIC/CRB 1404, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, 76000 Rouen, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Lequerré
authors.affiliation: Rheumatology Department, Amiens University Hospital, Inserm U1088, University of Picardie Jules Verne, 80054 Amiens, France.
authors.forename: Patrice
authors.initials: P
authors.lastname: Fardellone
authors.affiliation: Rheumatology Department, Rouen University Hospital, Inserm U905, CIC/CRB 1404, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, 76000 Rouen, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Le-Loët
authors.affiliation: Rheumatology Department, Roger Salengro Hospital, University of Lille 2, 59037 Lille Cedex, France.
authors.forename: Peggy
authors.initials: P
authors.lastname: Philippe
authors.affiliation: Department of Rheumatology, Caen University Hospital, Caen, France.
authors.forename: Christian
authors.initials: C
authors.lastname: Marcelli
authors.affiliation: Rheumatology Department, Rouen University Hospital, Inserm U905, CIC/CRB 1404, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, 76000 Rouen, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Vittecoq
authors.affiliation: Inserm, Unit 1036, Biology of Cancer and Infection, 38054 Grenoble, France; UJF-Grenoble 1, Biology of Cancer and Infection, 38054 Grenoble, France; CEA Comission at Atomic Energy and Alternative Energies, DRF/B(2)IG direction de la recherche fondamentale/BioScience and Biotechnology Institute of Grenoble, 38054 Grenoble, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Vilgrain
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000032:analysis* / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*; D001323:Autoantibodies / Q000032:analysis* / Q000276:immunology; D015415:Biomarkers / Q000032:analysis; D015820:Cadherins / Q000032:analysis* / Q000276:immunology; D015331:Cohort Studies; D000068800:Etanercept / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D012995:Solubility; D016896:Treatment Outcome; D000099152:Cadherin 5
chemical_list: D000068879:Adalimumab; D015703:Antigens, CD; D001323:Autoantibodies; D015415:Biomarkers; D015820:Cadherins; D000068800:Etanercept; D000099152:Cadherin 5
keywords: Adalimumab; Anti-vascular endothelial-cadherin antibody; Etanercept; Rheumatoid arthritis; Soluble VE cadherin